Nonarteritic Anterior Ischemic Optic Neuropathy Clinical Trial
Official title:
Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy
Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of
non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to
evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field
in patients with recent onset NAION (less than 6 weeks duration).
Patients and Methods: In this double-blind randomized clinical trial, 13 patients were
treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity,
color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks
after enrollment, and evaluated.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00561834 -
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
|
Phase 1 | |
| Completed |
NCT01131104 -
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
|
||
| Terminated |
NCT03547206 -
Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
|
Phase 2 |